Chet Bohac

514 total citations
21 papers, 340 citations indexed

About

Chet Bohac is a scholar working on Oncology, Immunology and Hematology. According to data from OpenAlex, Chet Bohac has authored 21 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 8 papers in Immunology and 7 papers in Hematology. Recurrent topics in Chet Bohac's work include CAR-T cell therapy research (9 papers), Immunotherapy and Immune Responses (7 papers) and Erythropoietin and Anemia Treatment (6 papers). Chet Bohac is often cited by papers focused on CAR-T cell therapy research (9 papers), Immunotherapy and Immune Responses (7 papers) and Erythropoietin and Anemia Treatment (6 papers). Chet Bohac collaborates with scholars based in United States, United Kingdom and France. Chet Bohac's co-authors include Loretta A. Williams, David Cella, Sharon K. Hunter, Seth M. Pollack, Aminah Jatoi, Edith P. Mitchell, Mario E. Lacouture, Robin L. Jones, Milan J. Anadkat and Neeta Somaiah and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Chet Bohac

20 papers receiving 331 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chet Bohac United States 10 223 109 86 54 51 21 340
Richard Mansour United States 9 152 0.7× 71 0.7× 34 0.4× 40 0.7× 62 1.2× 56 326
Shogo Kobayashi Japan 10 112 0.5× 53 0.5× 92 1.1× 30 0.6× 156 3.1× 50 317
Samip Master United States 10 136 0.6× 56 0.5× 37 0.4× 40 0.7× 86 1.7× 56 325
John Waller United Kingdom 10 107 0.5× 102 0.9× 94 1.1× 57 1.1× 77 1.5× 38 415
Omar Mamlouk United States 9 344 1.5× 158 1.4× 69 0.8× 42 0.8× 32 0.6× 33 476
Hirotsugu Ariizumi Japan 10 158 0.7× 44 0.4× 78 0.9× 34 0.6× 59 1.2× 26 246
P. Flemming Germany 12 169 0.8× 131 1.2× 39 0.5× 69 1.3× 16 0.3× 30 466
M. Martín Jiménez Spain 10 200 0.9× 133 1.2× 19 0.2× 27 0.5× 36 0.7× 56 323
Vaibhav Kumar United States 8 100 0.4× 84 0.8× 81 0.9× 28 0.5× 122 2.4× 25 311

Countries citing papers authored by Chet Bohac

Since Specialization
Citations

This map shows the geographic impact of Chet Bohac's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chet Bohac with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chet Bohac more than expected).

Fields of papers citing papers by Chet Bohac

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chet Bohac. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chet Bohac. The network helps show where Chet Bohac may publish in the future.

Co-authorship network of co-authors of Chet Bohac

This figure shows the co-authorship network connecting the top 25 collaborators of Chet Bohac. A scholar is included among the top collaborators of Chet Bohac based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chet Bohac. Chet Bohac is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Riedell, Peter A., Krish Patel, Yasmin Karimi, et al.. (2024). Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy. Blood. 144(Supplement 1). 4497–4497. 2 indexed citations
3.
Chen, Francine Z., Anushka De Costa, Ying Li, et al.. (2022). Abstract 330: Targeting B7-H3 in prostate cancer: Preclinical proof of concept with MGC018, an investigational anti-B7-H3 antibody-drug conjugate. Cancer Research. 82(12_Supplement). 330–330. 1 indexed citations
4.
Rasco, Drew, Ecaterina E. Dumbrava, Manish Sharma, et al.. (2022). 659 COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases. Regular and Young Investigator Award Abstracts. A690–A690. 1 indexed citations
5.
Shenderov, Eugene, Piotr J. Wysocki, Wen Xu, et al.. (2021). 620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion. Annals of Oncology. 32. S657–S659. 21 indexed citations
6.
7.
8.
Pollack, Seth M., Neeta Somaiah, Dejka M. Araujo, et al.. (2020). Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States. Cancer Medicine. 9(13). 4593–4602. 15 indexed citations
9.
Somaiah, Neeta, Matthew S. Block, Joseph W. Kim, et al.. (2019). First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clinical Cancer Research. 25(19). 5808–5817. 71 indexed citations
10.
Xu, Hairong, Lanfang Xu, Roberto Rodríguez, et al.. (2019). Epidemiology of Chemotherapy-Induced Anemia in Patients with Non-Hodgkin Lymphoma. The Permanente Journal. 23(3). 3 indexed citations
11.
12.
Chawla, Sant P., Seth M. Pollack, Matthew S. Block, et al.. (2018). Immune response, safety, and overall survival of NY-ESO-1+ soft tissue sarcoma patients treated with CMB305 therapy. Annals of Oncology. 29. viii578–viii578. 1 indexed citations
13.
Lacouture, Mario E., et al.. (2017). Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. Clinical Colorectal Cancer. 17(2). 85–96. 51 indexed citations
14.
Chawla, Sant P., Brian A. Van Tine, Seth M. Pollack, et al.. (2017). A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+ soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival. Annals of Oncology. 28. v523–v523. 12 indexed citations
15.
Williams, Loretta A., Chet Bohac, Sharon K. Hunter, & David Cella. (2016). Patient and health care provider perceptions of cancer-related fatigue and pain. Supportive Care in Cancer. 24(10). 4357–4363. 55 indexed citations
16.
Xu, Lanfang, Hairong Xu, Kimberly L. Cannavale, et al.. (2016). The effect of chemotherapy-induced anemia on dose reduction and dose delay. Supportive Care in Cancer. 24(10). 4263–4271. 18 indexed citations
17.
Bols, Alain, et al.. (2016). Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study. Cancer Management and Research. 8. 1–1. 9 indexed citations
18.
19.
Aapro, Matti, Volker Moebus, Ulrike Nitz, et al.. (2014). Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis. Annals of Oncology. 26(4). 688–695. 21 indexed citations
20.
Hedenus, Michael, Anders Österborg, Dianne Tomita, Chet Bohac, & Bertrand Coiffier. (2012). Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis. Leukemia & lymphoma. 53(11). 2151–2158. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard Mansour Breakdown of academic impact, for papers by Shogo Kobayashi Breakdown of academic impact, for papers by Samip Master Breakdown of academic impact, for papers by John Waller Breakdown of academic impact, for papers by Omar Mamlouk Breakdown of academic impact, for papers by Hirotsugu Ariizumi Breakdown of academic impact, for papers by P. Flemming Breakdown of academic impact, for papers by M. Martín Jiménez Breakdown of academic impact, for papers by Vaibhav Kumar
Rankless by CCL
2026